US-based biotechnology company United Therapeutics has reported the world’s first successful transplant of its xenothymokidney, dubbed UThymoKidney, into a living recipient.
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
Novartis is “actively” managing its existing relationships with Chinese service providers to mitigate risks if the Biosecure Act passes.
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
Liquidia wins against United Therapeutics in patent battle over PAH drug
United Therapeutics the First Comprehensive Review Publication
FDA approves Johnson & Johnson`s combo pill Opsynvi for PAH
United Therapeutics Announces $1 Billion Accelerated Share Repurchase Program
United Therapeutics to Take Lung-Drug Patent Fight to High Court